Dr. Scott Rocklage: Helping Early-Stage Life-Science Entrepreneurs Through 3AM Ventures

Venture capital firm 5AM Venture managing partner Dr. Scott Rocklage isn’t afraid to be involved in measured risk-taking. He has long been involved in cutting–edge medical research and the development of innovative drugs and medicines. He has helped the drugs Teslascan, Cubicin and Omniscan to get FDA approval, gotten several others into clinical trials and works with researchers, physician and entrepreneurs every day to turn their ideas into medicines, treatments and medical technologies to increase the length and quality of people’s lives.


For 30 years, since earning his BA in chemistry from UC Berkley and a chemistry PhD from MIT, Dr. Scott Rocklage has held executive positions with a wide range of biomedical companies, gained healthcare management experience and had strategic leadership responsibilities. He also over two dozens U.S. patents and his writings have appeared in more than 100 peer-reviewed scientific journals. He is a perfect fit for 5AM Ventures. There he can identify life science companies with viable ideas and get them the financial support and guidance they need to succeed.


Prior to becoming a venture partner at 5AM Ventures in 2003, Dr. Scott Rocklage was executive or board member with Cubist Pharmaceuticals, Nycomed Salutar, Relypsa, Novira, Semprus, Miikana and Ilypsa. He was also involved in research and development with Salutar, Catalytica and many others. Dr. Rocklage is currently on the chairman of the board at Cidara, Kinestral, Rennovia, Epirus and Pulmatrix. He also shared a lab with Nobel Prize winner Richard R. Schrock at the Massachusetts Institute of Technology. His focus is now on early stage life science based companies and the viability of their products.


Based in 5AM Ventures’ Boston, Massachusetts office, Dr. Scott Rocklage spends his days focused on life science, working with the portfolio management team and attending board meetings. He closely monitors the explosive growth in unique, targeted cancer treatments. Dr. Rocklage is excited about the medical developments he sees taking place in the near future. Known for being very well organized and a master of time management and prioritization, Dr. Rocklage also knows how important it is for new companies to have the right people on their staff and can share that with the companies in which 5AM Ventures invests.


Dr. Rocklage can help early stage companies to understand how important it is to stay true to what they do well and not stray away from their strengths and they can succeed.


Connect with Dr. Scott Rocklage on LinkedIn.

Jeremy Goldstein: Employees Benefit Consultant and Problem Solver

Jeremy Goldstein is considered to be one of the best in the industry for legal advice associated with workers benefits. Many corporations often seek his advice because of his experience — over 15 years in the legal industry as a lawyer. In addition, Jeremy Goldstein has established his own independent firm and worked with a comparable organization in New York.


Stock options have been a staple of all companies in America since its invention. Unfortunately, this may come to a halt because American corporations have stopped providing its employees the option. Jeremy Goldstein believes there are three main reasons corporations decide against stock options.


Firstly, Goldstein firmly believes that when the stock price drops below profitability, employees are no longer interested, nor motivated to depend on the option, rendering it useless. All businesses have expenses and often, they cause the price to dip, which leaves the stockholders on a hang. Secondly, many employees are skeptical about the option. They are fully aware of the economic downturns and situations, thus they tend to avoid stock options. Lastly, these options are a tremendous burden on the financial aspects of the business. In simpler terms, businesses constantly lose money when they have the stock option available.


Although the problems may seem evident, there are clear advantages to having stock options. For example, employees will prefer it over other compensation methods such as additional wages. In essence, they provide value to the employees.


As Jeremy Goldstein explains, the solution to this problem is the knockouts option. These have the same effect as the stock options but with a key difference, if the stock price falls below a certain limit, employees lose their option altogether. This could have several benefits and fixes many of the problems with stock options.


With such experience and expertise, the knockouts option is only one of several workers benefit solutions provided by Goldstein. He has played an important role in various companies such as Verizon, Chevron, and Merck. In addition, he has served on eminent boards all over America.


To learn more, read https://thereisnoconsensus.com/jeremy-goldstein-explains-knockout-options-help-employers/.